On February 16, 2021 Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, reported the company’s participation at upcoming healthcare investor conferences (Press release, Arch Oncology, FEB 16, 2021, View Source;utm_medium=rss&utm_campaign=arch-oncology-to-participate-in-upcoming-conferences [SID1234575107]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: SVB Leerink 9th Annual Healthcare Conference
Date: February 23, 2021

Event: Oppenheimer’s 31st Annual Healthcare Conference
Date: March 16, 2021, 4:30 – 5:00 pm ET